Rocket Pharmaceuticals, Inc. (RCKT)
2.565
-0.06
(-2.47%)
USD |
NASDAQ |
Oct 09, 16:00
2.59
+0.02
(+0.97%)
After-Hours: 20:00
Rocket Pharmaceuticals Enterprise Value : 29.14M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 29.14M |
| October 07, 2026 | 18.73M |
| October 06, 2026 | 12.71M |
| October 05, 2026 | 26.95M |
| October 02, 2026 | 21.47M |
| October 01, 2026 | 24.76M |
| September 30, 2026 | 29.14M |
| September 29, 2026 | 24.76M |
| September 28, 2026 | 26.95M |
| September 25, 2026 | 25.31M |
| September 24, 2026 | 35.71M |
| September 23, 2026 | 71.86M |
| September 22, 2026 | 108.01M |
| September 21, 2026 | 99.24M |
| September 18, 2026 | 110.20M |
| September 17, 2026 | 124.44M |
| September 16, 2026 | 122.25M |
| September 15, 2026 | 114.58M |
| September 14, 2026 | 116.77M |
| September 11, 2026 | 108.01M |
| September 10, 2026 | 122.25M |
| September 09, 2026 | 138.68M |
| September 08, 2026 | 147.44M |
| September 04, 2026 | 163.87M |
| September 03, 2026 | 156.21M |
| Date | Value |
|---|---|
| September 02, 2026 | 163.87M |
| September 01, 2026 | 149.63M |
| August 31, 2026 | 148.54M |
| August 28, 2026 | 163.87M |
| August 27, 2026 | 137.58M |
| August 26, 2026 | 141.97M |
| August 25, 2026 | 155.11M |
| August 24, 2026 | 127.73M |
| August 21, 2026 | 125.53M |
| August 20, 2026 | 122.25M |
| August 19, 2026 | 140.87M |
| August 18, 2026 | 106.91M |
| August 17, 2026 | 113.48M |
| August 14, 2026 | 121.15M |
| August 13, 2026 | 106.91M |
| August 12, 2026 | 114.58M |
| August 11, 2026 | 124.44M |
| August 10, 2026 | 139.77M |
| August 07, 2026 | 136.49M |
| August 06, 2026 | 128.82M |
| August 05, 2026 | 124.44M |
| August 04, 2026 | 117.87M |
| August 03, 2026 | 114.58M |
| July 31, 2026 | 81.72M |
| July 30, 2026 | 92.67M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.347B |
| Oncolytics Biotech, Inc. | 64.19M |
| Sangamo Therapeutics, Inc. | 49.79M |
| Sarepta Therapeutics, Inc. | 2.181B |
| Anixa Biosciences, Inc. | 85.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 123.21M |
| Total Expenses (Quarterly) | -123.21M |
| EPS Diluted (Quarterly) | 1.076 |
| Earnings Yield | -7.02% |
| Normalized Earnings Yield | -7.025 |